Robotic versus open pancreatic surgery: a propensity score-matched cost-effectiveness analysis
- PMID: 35312854
- PMCID: PMC9399018
- DOI: 10.1007/s00423-022-02471-2
Robotic versus open pancreatic surgery: a propensity score-matched cost-effectiveness analysis
Abstract
Background: Robotic pancreatic surgery (RPS) is associated with high intraoperative costs compared to open pancreatic surgery (OPS). However, it remains unclear whether several advantages of RPS such as reduced surgical trauma and a shorter postoperative recovery time could lead to a reduction in total costs outweighing the intraoperative costs. The study aimed to compare patients undergoing OPS and RPS with regards to cost-effectiveness in a propensity score-matched (PSM) analysis.
Methods: Patients undergoing OPS and RPS between 2017 and 2019 were included in this monocentric, retrospective analysis. The controlling department provided financial data (costs and revenues, net loss/profit). A propensity score-matched analysis was performed or OPS and RPS (matching criteria: age, American society of anesthesiologists (ASA) score, gender, body mass index (BMI), and type of pancreatic resection) with a caliper 0.2.
Results: In total, 272 eligible OPS cases were identified, of which 252 met all inclusion criteria and were thus included in the further analysis. The RPS group contained 92 patients. The matched cohorts contained 41 patients in each group. Length of hospital stay (LOS) was significantly shorter in the RPS group (12 vs. 19 days, p = 0.003). Major postoperative morbidity (Dindo/Clavien ≥ 3a) and 90-day mortality did not differ significantly between OPS and RPS (p > 0.05). Intraoperative costs were significantly higher in the RPS group than in the OPS group (7334€ vs. 5115€, p < 0.001). This was, however, balanced by other financial categories. The overall cost-effectiveness tended to be better when comparing RPS to OPS (net profit-RPS: 57€ vs. OPS: - 2894€, p = 0.328). Binary logistic regression analysis revealed major postoperative complications, longer hospital stay, and ASA scores < 3 were linked to the risk of net loss (i.e., costs > revenue).
Conclusions: Surgical outcomes of RPS were similar to those of OPS. Higher intraoperative costs of RPS are outweighed by advantages in other categories of cost-effectiveness such as decreased lengths of hospital stay.
Keywords: Cost analysis; Pancreatic surgery; Robotic surgery.
© 2022. The Author(s).
Conflict of interest statement
C.B., L.T., M.F., L.M.H., A.W., M.M.M., K.H.H., T.W., and F.K.: none, M.S.: Merck Serono GmbH, Bayer AG, ERBE Elektromedizin GmbH, Amgen Inc., Johnson & Johnson Medical GmbH, Takeda Pharmaceutical Limited, Olympus K.K., Medtronic GmbH, Intuitive Surgical Inc.; T.M.: Intuitive Surgical Inc.; J.P.: Intuitive Surgical Inc., Johnson & Johnson Medical GmbH.
Figures
Similar articles
-
International multicentre propensity score-matched analysis comparing robotic versus laparoscopic right posterior sectionectomy.Br J Surg. 2021 Dec 1;108(12):1513-1520. doi: 10.1093/bjs/znab321. Br J Surg. 2021. PMID: 34750608 Free PMC article.
-
A Propensity Score-Matched Analysis of Robotic vs Open Pancreatoduodenectomy on Incidence of Pancreatic Fistula.JAMA Surg. 2017 Apr 1;152(4):327-335. doi: 10.1001/jamasurg.2016.4755. JAMA Surg. 2017. PMID: 28030724 Free PMC article.
-
Impact of three-dimensional-printing technology guidance on surgical outcomes for retroperitoneal sarcoma: A propensity score-matched study.Cancer. 2025 Jan 1;131(1):e35452. doi: 10.1002/cncr.35452. Epub 2024 Jul 3. Cancer. 2025. PMID: 38959293
-
The impact of high body mass index on patients undergoing robotic pancreatectomy: A propensity matched analysis.Surgery. 2020 Mar;167(3):556-559. doi: 10.1016/j.surg.2019.11.002. Epub 2019 Dec 11. Surgery. 2020. PMID: 31837833
-
Robotic Vascular Resection in Pancreatic Ductal Adenocarcinoma: A Systematic Review.J Clin Med. 2024 Mar 29;13(7):2000. doi: 10.3390/jcm13072000. J Clin Med. 2024. PMID: 38610766 Free PMC article. Review.
Cited by
-
International consensus guidelines on robotic pancreatic surgery in 2023.Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):89-104. doi: 10.21037/hbsn-23-132. Epub 2024 Jan 18. Hepatobiliary Surg Nutr. 2024. PMID: 38322212 Free PMC article. Review.
-
Pancreatic Neuroendocrine Tumors: What Is the Best Surgical Option?J Clin Med. 2024 May 20;13(10):3015. doi: 10.3390/jcm13103015. J Clin Med. 2024. PMID: 38792555 Free PMC article. Review.
-
Robotic surgery reduces the consumption of medical consumables: cost analysis of robotic pancreatic surgery from a tertiary hospital in China.J Robot Surg. 2024 Aug 12;18(1):320. doi: 10.1007/s11701-024-02075-6. J Robot Surg. 2024. PMID: 39133350
-
Current landscape of minimally invasive pancreatectomy for neoplasms: A retrospective cohort study.World J Surg. 2025 Jan;49(1):241-252. doi: 10.1002/wjs.12408. Epub 2024 Nov 22. World J Surg. 2025. PMID: 39578686 Free PMC article.
References
-
- Wabitsch S, Kästner A, Haber PK, Benzing C, Krenzien F, Andreou A, Kamali C, Lenz K, Pratschke J, Schmelzle M. Laparoscopic versus open liver resection for benign tumors and lesions: a case matched study with propensity score matching. J Laparoendosc Adv Surg Tech A. 2019;29(12):1518–1525. doi: 10.1089/lap.2019.0427. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous